logo
EDAN Highlights Commitment to Global Health at GHF 2025 Satellite Symposium, a Side Event of the World Health Assembly

EDAN Highlights Commitment to Global Health at GHF 2025 Satellite Symposium, a Side Event of the World Health Assembly

Korea Herald25-05-2025
GENEVA, May 25, 2025 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global medical device company, participated in the Geneva Health Forum (GHF) 2025 Satellite Symposium, held as a side event of the World Health Assembly (WHA). Titled "China's Medical Technology Innovation and Its Implementation for Global Health," the event took place on May 20 in Geneva and was co-organized by Tsinghua University and the Université de Genève. It brought together innovators, policymakers, and development partners to explore how Chinese medical technology is advancing equitable healthcare, particularly in low- and middle-income countries (LMICs).
Representing EDAN, Co-Founder Mr. Xicheng Xie delivered a keynote sharing the company's experience in delivering accessible innovation to underserved communities. "Real innovation isn't just about cutting-edge technology — it's about bringing the right solutions to the people who need them the most," said Mr. Xie, reflecting on the company's three-decade journey and the evolving meaning of innovation.
In that spirit, Mr. Xie highlighted EDAN's efforts to develop medical technologies that are accessible, practical, and impactful in real-world settings. He shared detailed of an ongoing initiative using EDAN's Nano Series handheld diagnostic ultrasound system to support basic prenatal care in resource-limited environments. The project focuses on equipping primary healthcare workers with tools for early screening and timely referral for at-risk pregnancies. He also noted other impactful technologies, including palm-sized fetal dopplers, EDAN's IQ intelligent algorithm, and its smart ECG web platform — each designed to bridge infrastructure gaps and reduce reliance on scarce medical personnel.
With a long-standing presence across both high-end and resource-limited markets, EDAN has built a truly global footprint – from Europe to Africa. To strengthen local engagement and ensure more responsive service, it has established 22 subsidiaries worldwide. This localized support, combined with a commitment to frontline feedback, drives continuous product improvement and meaningful impact.
EDAN is also actively involved in a range of meaningful projects across LMICs, working alongside NGOs, public health agencies, and development partners. These include maternal health and women's care initiatives in South Africa, portable diagnostic deployments in West Africa, and ultrasound screening programs in Latin America. Each year, nearly 1,000 ultrasound devices are deployed globally through NGO-led programs. These partnerships not only expand access to essential care but also help build local capacity through training and support.
"At EDAN, we believe in bringing innovation and value together to improve the human condition," Xie concluded. "That mission is at the core of everything we do — from product design to global partnerships."
As EDAN celebrates its 30th anniversary in 2025, the company remains steadfast in its mission to deliver innovation that matters — especially for those who need it most.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions
KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions

Korea Herald

time8 hours ago

  • Korea Herald

KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions

SHANGHAI, July 26, 2025 /PRNewswire/ -- The world premiere of KEENON Robotics' bipedal humanoid service robot, XMAN-F1, takes center stage at the World Artificial Intelligence Conference (WAIC) 2025 in Shanghai from July 26 to 29, where the pioneer in embodied intelligence showcases its latest innovations on the global stage for breakthrough AI advancements. Transforming its showground into an Embodied Service Experience Hub, KEENON immerses visitors in three interactive scenarios—medical station, lounge bar, and performance space—highlighting how embodied AI solution is actively reshaping future lifestyles and industrial ecosystems. At the event, XMAN-F1 emerges as the core interactive demonstration, showcasing human-like mobility and precision in service tasks across diverse scenarios. From preparing popcorn to mixing personalized chilled beverages such as Sprite or Coke with adjustable ice levels, the robot demonstrates remarkable environmental adaptability and task execution. Scheduled stage appearances feature XMAN-F1 autonomously delivering digital presentations and product demos, powered by multimodal interaction and large language model technologies. Its fluid movements and naturalistic gestures establish it as the primary focus of attention, with visitors gathering to witness its engagement live. The demonstration spotlights further multi-robot collaboration in specialized environments. At the medical station, the humanoid XMAN-F1 partners with logistics robot M104 to create a closed-loop smart healthcare solution. The bar area features a highlight collaboration with Johnnie Walker Blue Label—the world's leading premium whisky—where robotic bartenders work alongside delivery robot T10 to craft and serve bespoke beverages. The seamless multi-robot integration not only enhances operational efficiency but signals the dawn of robotic system interoperability, moving far beyond single-task automation. According to IDC's latest report, KEENON leads the commercial service robot sector with 22.7% of global shipments and holds a definitive 40.4% share in food delivery robotics. At WAIC 2025, the company reinforces its market leadership while presenting its ecosystem-based strategy for cross-scenario embodied intelligence solutions. Looking ahead, KEENON will continue driving innovation in embodied intelligence, combining cutting-edge R&D and global partnerships to unlock the full potential of 'Robotics+' applications worldwide.

CGTN: How China's economy remains vibrant despite U.S. tariff war
CGTN: How China's economy remains vibrant despite U.S. tariff war

Korea Herald

time10 hours ago

  • Korea Herald

CGTN: How China's economy remains vibrant despite U.S. tariff war

BEIJING, July 26, 2025 /PRNewswire/ -- With Chinese Vice Premier He Lifeng to hold economic and trade talks with the United States in Sweden later this month, the strength and resilience of the Chinese economy is in the limelight once again. This round of talks, mutually agreed upon by both nations, is not only a diplomatic engagement but also a testament to China's enduring economic vitality in a complex international environment. Recent statistics underscore the robustness of China's economy. In the first half of 2025, the GDP grew by an impressive 5.3 percent year on year, surpassing market expectations despite global headwinds. This number reflects more than temporary growth; it exhibits the structural resilience and adaptability of an economy that continues to evolve and upgrade. Domestic demand emerged as the cornerstone of growth, contributing 68.8 percent to GDP expansion in this period. Initiatives such as large-scale equipment upgrades and consumer goods trade-in programs have effectively stimulated spending, cushioning China's economy from external shocks. In the first five months of 2025 alone, China's consumer goods trade-in program generated 1.1 trillion yuan ($153.1 billion) in sales, surpassing the figure for entire 2024. Boosted by the program, China's retail sales of consumer goods grew 5 percent year on year in the past six months – 0.4 percentage point faster than the growth recorded in the first quarter. While external uncertainties have introduced some pressure, China's trade diversification and the steady output of high-tech manufacturing and service industries have provided strong support to the economy. Though China's trade with some Western countries declined, its trade with Belt and Road partners, ASEAN countries, the European Union, and African nations saw respective increases of 4.7 percent, 9.6 percent, 3.5 percent, and 14.4 percent in the first half of 2025. This expansion of trade relationships has helped China reduce its reliance on any one market, lessening the impact of some Western economies' protectionist policies. China's resilience reverberates beyond its borders. As a crucial driver of global growth, China's steady economic performance boosts international market confidence and provides a stabilizing influence amid global uncertainties. Through continued focus on quality growth and opening up, China offers the international community a reliable engine for shared prosperity. A recent report from the U.S.-China Business Council indicates that 82 percent of American companies operating in China turned a profit in 2024. Though many cited the uncertainties in China-U.S. relations and tariffs as their main worry, the Chinese market continues to be crucial for them. Trade tensions pose obstacles, yet they have not crippled the resilience in the Chinese economy. The upcoming Beijing-Washington talks in Sweden demonstrate China's willingness to tackle differences via negotiations. While obstacles remain, China's ability to sustain growth, adapt to changing global landscapes, and engage constructively with international partners signals a future of shared opportunities and mutual advancement.

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

Korea Herald

time16 hours ago

  • Korea Herald

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the " Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: The hair growth assessment (" HGA") indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013). The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store